E7-targeted T cell treatment for HPV-related cancers
Official title: E7 TCR-T cell therapy for HPV-associated cancers
Funded at Rutgers Biomedical and Health Sciences · NIH-11125763 · Data updated 2026-11-12
This offers people with advanced HPV-related cancers personalized T cells engineered to attack the HPV E7 protein.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $627,893 |
| NIH project number | 5U01CA287904-02 |
| Project ID | NIH-11125763 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with advanced or metastatic HPV-positive cancers that express E7 who have exhausted standard treatments and can undergo leukapheresis and cell infusion.
✕Less likely to help
People whose tumors are not driven by HPV/E7, who are too frail for cell therapy, or who cannot travel to the treatment site are unlikely to benefit.
What this research studies
If I join, doctors will collect my own immune cells and reprogram them in the lab with a T-cell receptor that recognizes the HPV E7 protein, then grow many of those cells and infuse them back into me. The treatment is aimed at cancers caused by HPV, including cancers of the cervix, throat, anus, vulva, vagina, and penis that make the E7 protein. Early testing has shown the approach can be given safely and has produced tumor responses in some patients, and this program seeks to treat more people and improve the process. Joining would involve blood collection (leukapheresis), a hospital visit for the cell infusion, and regular follow-up to check for side effects and response.
Why it matters
Potential benefit: If successful, the therapy could shrink or eliminate tumors that make the HPV E7 protein and lead to durable remissions.
How similar studies have gone: Early-phase clinical work with E7-directed TCR-T cells has shown safety and some clinical responses, but larger studies are needed to confirm lasting benefit.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Hinrichs, Christian — Rutgers Biomedical and Health Sciences
- Study coordinator: Hinrichs, Christian
Related research
Other NIH-funded projects on the same topics.
-
Methylation and metabolism signals linked to lung function in kids with asthma
This grant looks at how genes, environment, and small chemical changes in the body together affect how lung function changes over time in children with asthma.
-
FEND-TB: Faster, better TB tests for all ages
A multi-institutional project aims to develop and validate faster TB diagnostic tools and drug-susceptibility tests so people of all ages, including children and those with extrapulmonary TB, can get quicker and more accurate results.
-
FEND-TB: Accelerating TB Diagnostics and Drug Susceptibility Testing
A multi‑institution collaboration will test new TB diagnostic tools and rapid drug-susceptibility tests to improve detection and treatment for people of all ages, including children and those with hard-to-diagnose TB.
-
Game-based mobile app to help pregnant women with overweight/obesity manage weight in Nepal
A new app designed for pregnant women in Nepal with overweight or obesity to help manage weight gain during pregnancy and reduce weight retention after birth.
-
Environmental factors and Lewy body dementia: linking claims data with lab work
Aims to find environmental factors that influence Lewy body dementia by combining big health data with lab studies, to understand what might worsen the condition and who is most at risk.
-
Identifying how ableism affects pregnancy and postpartum care for women with intellectual and developmental disabilities on Medicaid
This grant studies how bias and barriers in the healthcare system affect pregnancy and postpartum outcomes for women with intellectual and developmental disabilities who are on Medicaid and their babies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.